The stock of Vertex Pharmaceuticals Incorporated VRTX has declined almost 13% in the past six months. A key reason for the stock price decline was unimpressive data from a phase II study on its key ...

The HAELO trial will assess the therapy’s safety and efficacy in 60 adult subjects with Type I or Type II HAE.

In this review of RNA therapies, we paint an overview of what’s going on in a field that is addressing a number of diseases.

There are 20 cell and gene therapies on Europe's market versus 43 in the U.S. Find out more about this ecosystem.